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Abstract
Hemothorax (HT) is a life-threatening condition, mainly iatrogenic and poorly explored in Liver Transplantation (LT) recipi-
ents. The aim of this study is to report and analyze for the first time incidence and outcomes of HT in LT recipients, as well 
as to suggest a management strategy. Data concerning 7130 consecutive adult liver and liver–kidney transplant recipients 
were retrospectively collected from ten Transplantation Centers’ institutional databases, over a 10-year period. Clinical 
parameters, management strategies and survival data about post-operative HT were analyzed and reported. Thirty patients 
developed HT during hospitalization (0.42%). Thoracentesis was found to be the most common cause of HT (16 patients). 
A non-surgical management was performed in 17 patients, while 13 patients underwent surgery. 19 patients developed tho-
racic complications after HT treatment, with an overall mortality rate of 50%. The median length of stay in Intensive Care 
Units was 22 days  (IQR25–75 5–66.5). Postoperative hemothorax is mainly due to iatrogenic causes in LT recipients. Despite 
rare, it represents a serious complication with a high mortality rate and a challenging medical and surgical management. Its 
occurrence should always be prevented.
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Introduction
Liver transplantation (LT) is increasingly performed 
worldwide over the lasts 5 decades to treat end-stage liver 
disease. Despite the improvements in the field of immu-
nosuppression and clinical management, the rate of post-
operative complications after LT is still high [1, 2]. The 
most common post-operative thoracic complication after 
LT is pleural effusion [3]. The incidence of pleural effu-
sion stands between 32 and 47% and can be due to sub-
diaphragmatic surgery, to central vein (jugular, subcla-
vian) line (CVL) insertion or to percutaneous liver biopsy 
(PLB). In 22–52% of the cases a chest drainage (CT) is 
required, with the risk of complications like pneumothorax 
and hemothorax [3, 4]. Moreover, LT recipients could suf-
fer from persistent coagulopathy because of an impaired 
production of coagulation factors, as well as low platelets 
number (LPN) and/or thrombopathy. Persistent coagu-
lopathy in LT recipients is probably secondary to previ-
ous cirrhosis status, hypersplenism, and/or a delayed graft 
function. The risk for hemothorax (HT) is then higher than 
general population. Clinicians must be aware of such a 
complication, to best prevent it and to make a timely diag-
nosis and treatment.
The aim of this observational international study was 
to report causes and incidence of HT and to discuss the 
strategies to manage this rare but life-threatening condi-
tion in LT recipients.
Methods
Study design and data sources
This is a multicenter observational retrospective study. 
Data regarding consecutive adult LT recipients undergoing 
single liver transplantation or liver–kidney transplantation 
between 1st January 2009 and 31 December 2019 were ret-
rospectively collected from the institutional databases of 
ten International Transplant Units. Data regarded patient’s 
demographics, diagnosis (hemothorax) and procedures 
(thoracentesis, percutaneous liver biopsy, thoracotomy, 
thoracoscopy, intercostal embolization) according to the 
International Classification of Diseases (ICD-10), hospitality 
status and length of hospital stay. Data regarding the man-
agement of HT, coagulation tests, Child–Turgot–Pugh score, 
MELD score, morbidity and mortality were also recorded. 
Patients younger than 18 years, patients with genetic coag-
ulopathies, recipients receiving combined liver–lung or 
liver–heart transplantations and patients receiving organs 
from living donors were excluded from the study.
The study was approved by the local Institutional Review 
Board (IRB #2019-01-234) and reporting was made accord-
ing to STROCCS guidelines [5].
Definitions
Diagnosis of HT was clinical in patients who already has a 
chest tube (CT) or radiological with computed tomography 
(CT) scan.
Type of treatment provided, beyond medical resuscita-
tion, was defined “non-surgical” when CT/US-guided per-
cutaneous procedures and/or radiologic embolization (RE) 
were performed.
Statistical analysis
Continuous data are expressed as mean and standard devia-
tion (SD) or median and interquartile range (IQR) depend-
ing on whether or not they have a normal distribution. Cat-
egorical data are expressed as frequencies and associated 
percentages. All survival analyses were performed using 
Kaplan–Meier to compute median and 95% CI. Median 
follow-up was calculated using reverse Kaplan–Meier meth-
odology. The statistical analysis has been conducted using 
the SPSS software (version 26.0).
Results
 Patients’ characteristics
A total of 7130 consecutive adult LT recipients from ten 
Transplantation Units over a 10-year period met the inclu-
sion criteria. All the patients had undergone CVL insertion, 
while 598 patients (8.3%) had undergone PLB, before or 
during LT. 2852 (40%) patients developed a pleural effusion 
after LT, and 1053 (14,8%) underwent thoracentesis.
30 patients meeting inclusion criteria developed HT 
after LT and were further analyzed, accounting for over-
all incidence of 0.42%. Mean age of patients with HT was 
48.5 years (range 18–67). Mean Child–Pugh score was B9 
(range A6–C13) and mean MELD score was 22 (range 
6–40). Indications for LT in these 30 patients were alco-
holic cirrhosis (n = 8), hepatitis C virus (n = 5), hepatocel-
lular carcinoma (HCC) (n = 4), echinococcosis (n = 2), non-
alcoholic steatohepatitis (NASH) (n = 2), polycystic disease 
(n = 2) and other single miscellaneous cases. It was the sec-
ond LT in four patients, while in one case it was the third 
LT. 12 patients had previous respiratory disorders before LT 
(5 heavy smokers, 3 hydrothorax, 1 pulmonary hyperten-
sion, 1 emphysema and 2 mild pleural effusions), but none 
of them underwent thoracic surgery or thoracentesis before 
transplantation.
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3 patients had anticoagulation therapy, 5 anti-platelets 
therapy and 12 had both anticoagulant and anti-platelet 
therapy. Prior to HT, the mean prothrombin time (PT) was 
70.2% (± 22.6) and mean platelets count was of 121.000 plt/
mm3(± 18.998). In particular, platelet count was < 50,000 in 
4 patients (13.3%).
All features of patients with HT are detailed in Table 1.
Causes and timing of HT occurrence
Thoracentesis, even if performed under ultrasound guid-
ance (US) in 62% of the cases, represented the most com-
mon cause of HT (53.3% of the patients). Specifically, in 
the thoracentesis subgroup, incidence of HT was as high 
as 1.52% (16/1053). Liver biopsy was responsible for HT 
in 6 patients (20%), with an incidence of 1% on this proce-
dure, while CVL insertion accounted for other 3 patients 
(10%, with an incidence of 0.04%). Moreover, HT was con-
sequent to diaphragmatic resection performed during LT in 
1 patient and to percutaneous trans-hepatic cholangiography 
in another one. No evident cause of HT was detected in 3 
patients (Fig. 1). The median delay between LT and HT 
apparition was of 12 days.
HT management
Anticoagulation therapy and anti-platelet drugs was always 
discontinued and antagonized if possible. Fluid resusci-
tation was immediately provided. A total of 25 (83.3%) 
patients received blood transfusions. Mean red blood cells 
(RBC) units transfused was 5.68 (± 2.6). A percutaneous 
24- or 26-French CT was inserted in 25 (83.3%) patients to 
decompress pleural cavity and to monitor bleeding. Platelets 
transfusion was provided before thoracentesis when platelets 
count was less than 50,000.
In 17 patients (56.67%) a non-surgical treatment was 
provided: 13 (43.3%) patients needed CT placement only, 
2 (6.67%) patients required CT and an intercostal arterial 
Table 1  Patients’ characteristics
M male, F female, LT liver transplantation, HT hemothorax, BMI 
body mass index, HCC hepato cellular carcinoma, NASH nonalco-
holic steato-hepatitits, HCV hepatitis C virus, HBV hepatitis B virus, 
n number, yrs years
Characteristics Patients with 
HT post LT 
N = 30
Age, mean (range), yrs 48,5 (16–66)
Gender (M/F), n (%) 18 (60)/12 (40)
BMI, Median (range) 24.4 (18–31.5)
Number of LT, n (%)
 Primary LT 25 (83.3)
 Secondary LT 4
 Third LT 1





 Polycystic hepatic disease 2 (6,6)
 Echinococcosis 2 (6,6)
 HBV 1 (3,3)
 Autoimmune hepatitis 1 (3,3)
 Hyperoxaluria 1 (3,3)
 Fulminant hepatic failure 1 (3,3)
Primary sclerosing cholangitis 1 (3,3)
 Primary non function 1 (3,3)
Scores
 Child–Pugh score, mean (range) 9 (6–13)
 MELD score, mean (range) 22 (6–40)






 Mild pleural effusion 1
 Prior thoracic surgery 0
 Thoracentesis 0
 Anticoagulant or anti-platelet drugs before LT 13
Post-LT pleural effusion, n (%) 2852 (40)
Donor age yrs, Mean (range) 69 (56–89)
Fig. 1  Causes of the hemothorax. LT liver transplantation, PLB per-
cutaneous liver biopsy, PTC percutaneous trans-hepatic cholangio-
graphy; Spontaneous (or undetermined)
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embolization and 2 (6.67%) patients benefited from an arte-
rial intercostal embolization with no CT.
Surgical treatment was reserved to 13 (43.3%) patients: 
10 (33.3%) patients had thoracotomy and in 3 (10%) patients 
had three-port thoracoscopy for exploration. No « thoracic 
packing» had to be performed. For more information on HT, 
see Table 2.
Management strategies provided are resumed in Fig. 2.
Short and long‑term outcomes of HT treatment
Nineteen patients (63.3%) developed thoracic complications 
after HT treatment: 8 (26.67%) patients had an acute respira-
tory distress syndrome (ARDS), 6 (20%) patients needed 
prolonged mechanical ventilation support, 2 (6.67%) patients 
presented a pleural abscess, one patient had a severe car-
dio-respiratory shock, another one a retained HT and one 
patient had a residual pleural effusion treated medically. 
The median length of the ICU hospital stay was of 17 days 
 (IQR25–75 7.5–35.5). Data on morbidity and mortality are 
summarized in Table 3. We report a mean interval between 
diagnosis of HT and surgery, when indicated, of 6 h (rang-
ing from 1 to 32). No significant differences in morbidity 
and mortality rates were detected in patients who received 
non-surgical treatment compared to the surgical one. The 
overall mortality rate was 50% (n = 15), after a median 
Table 2  Features of the 
hemothorax
PT prothrombine time, RBC red blood cell, n number, h hours
a These number before platelet transfusion
Characteristics Patients with HT 
post LT N = 30
Simultaneous pneumothorax, n (%) 20 (66.7)
Side of the hemothorax, n (%)
 Right 21 (70)
 Left 9
Anti-coagulations/platelets drugs after LT, n (%) 20 (66.7)
 Anticoagulation only 3
 Antiplatelet only 5
 Anticoagulation + antiplatelet 12
Hemostase Biologic parameters the day of HT
 PT (%), Mean (range) 70,2 (22,6)
 Platelets count plt/mm3, mean (SD) 121,000 (18.998)a
 < 70,000 plt/mm3 9
 < 50,000 plt/mm3 4
Transfusion
 Number of patients transfused, n (%) 25 (83.3)
 RBC units, median (range) 6 (0–17)
Management of HT
 Delay between HT and LT, Median days, (range) 175 (1–3232)
  < 30 days after LT, n patients (%) 18 (60)
 Initially percutaneous chest tube treatment, n (%) 25 (83.3)
 Use of guided echography, n (%) 12 (40)
 Surgical treatment, n (%) 13 (43.3)
Delay between chest-tube and surgery (h) median (range) 6 (1–32)
Fig. 2  Performed treatments
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follow-up of 42 months. The median Overall Survival (OS) 
was 28.5 months (Fig. 3).
Discussion
The most common postoperative pulmonary complication 
following LT is pleural effusion, with a reported incidence 
between 32 and 47%. Pleural effusion after LT, most com-
monly identified unilaterally on the right side, is known to 
be associated with a poorer short-term outcomes, with a the 
need for thoracentesis varies between 22 and 52% in litera-
ture [3]. Similarly, in our series, 14.8% of the patients under-
going LT had a CT in the post-transplant period (n = 1055). 
CT placement is not risk free and its benefits must be bal-
anced against possible complications. The most common 
and frightened complications of the procedure, as well as 
CVL insertion or PBL, are pneumothorax and hemothorax. 
In cirrhotic patients, the reported incidence of pneumothorax 
is 8.4% and 0–2% for HT [6, 7]. Currently, no study address-
ing the same issue for LT recipients is available in literature.
In our cohort of LT recipients, the overall incidence of 
HT was of 0.42%. In the thoracentesis subgroup, incidence 
of HT was as high as 1.52% (16/1053). Fortunately, the 
risk of HT due to thoracentesis is low even in critically ill 
patients. In the meta-analysis by Gordon et al., there have 
been 6 cases reported among 6605 procedures performed 
[8]. Based on our analysis, HT is still a rare and very severe 
complication event after thoracentesis in LT recipients. Mor-
tality accounted for as much as 50% of the patients.
Due to its rarity and its severe features, HT management 
is still debated and no recommendations have been reported, 
at the time. Moreover, major difficulty in our specific popu-
lation was the presence in some of the patients of a persis-
tent coagulopathy and/or residual portal hypertension’s signs 
(low PT, low platelet count). This happens in the early post-
transplant period when a delayed graft function occurs [9]. A 
delayed graft function recovery is more frequent when mar-
ginal liver donors are used [10]. Interestingly, in our cohort, 
the mean donor age was 69 years and mean BMI was 27.9.
Currently, no optimization of coagulation is recom-
mended before CT insertion and drainage of non-urgent 
cases should be avoided if international normalization 
ratio (INR) is > 1.5 [11]. Urgent cases could be managed 
with the administration of fresh frozen plasma and plate-
let concentrates when invasive interventions are necessary. 
Pulchalski et al. also suggested that thoracentesis may be 
Table 3  Outcomes after hemothorax treatment
ARDS acute respiratory distress syndrome, Clavien–Dindo classifica-
tion: (IV-A) life-threatening complication requiring IC/ICU manage-
ment (single organ dysfunction); (V) death of a patient
Characteristics Patients with 
HT post LT 
N = 30
Median follow-up, months  (IQR25–75) 42 (12–180)
Thoracic complications, n (%) 19 (63.3)
 ARDS 8
 Prolonged mechanical ventilation 6
 Pleural abscess 2
 Residual uninfected pleural effusion 1
 Retained hemothorax 1
 Cardio-respiratory shock 1
ICU hospital stay (days), median  (IQR25–75) 12 (5–66.5)
Survival rate, n (%) 15 (50)
Fig. 3  Flowchart for an inter-
costal procedure (thoracentesis, 
biliary drainage, liver biopsy) 
in LT recipients. CTS computer 
tomography scan, US ultra-
sound, Hb hemoglobin level, 
LT liver transplantation, PTL 
platelet count, PT(%) prothrom-
bin time
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safely performed without prior correction of coagulopathy, 
thrombocytopenia, or medication-induced bleeding risk 
[12]. Anyway, all these series did not consider the particular 
population of LT recipients who can develop hemorrhagic 
complications even with subnormal coagulation parameters. 
In fact patients that developed HT in our series had a mean 
PT of 77% (± 22.6) and a mean platelet count of 121,000 
(± 18.998). Thus, it’s very important to make any possible 
effort to detect coagulopathy and thrombopaty, as well as 
try to meticulously improve coagulation before any invasive 
intervention on LT patients.
Few studies analyzing the complications due to invasive 
procedures in the LT patient are available. Filingeri et al. 
reported 2 cases of pneumothorax and one case (0.12%) of 
HT after 847 percutaneous liver biopsies performed with 
intercostal approach in LT recipients [13]. Pérez Roldán 
et al. reported 4 (0.9%) cases of HT over 438 PLB: two 
patients required thoracotomy and mortality rate was as high 
as 25% [14]. Moreover, Jankovic et al. reported a fatal case 
of HT following CVL insertion [15].
We did not identify the origin of HT in 3 (10%) of our 
patients after LT. In these undetermined cases, various 
causes more or less rare could be mentioned.
In addition to coagulopathy attention and optimization, 
performing the CT insertion under ultrasound (US) guide is 
safer, to avoid the risk of HT [4, 11, 16]. Miraglia et al. rec-
ommends ultrasound-guided placement of pigtail catheters 
in supine position for pleural effusion [17]. As high as 40% 
(12 patients) of our population had CT placement using ana-
tomical landmarks and no US guide, since our study has an 
inclusion period that started partially before the publication 
of International Recommendations on thoracentesis [11]. 
Surely, the CT insertion in Intensive Care Unit (ICU) and in 
dorsal position under US guide is safer and is integrated in 
our practice as standard after 2015.
No studies focused yet on intercostal artery emboliza-
tion to stop chest bleeding in LT recipients. We think that 
radiologic embolization could be very useful in same cases 
and highly effective. It should be considered as a valuable 
tool in the therapeutic arsenal for non-catastrophic HT (slow 
but persistent bleeding with no hemodynamic compromise) 
when available.
According to previous publications [18–20], we designed 
a protocol to reduce the risk of HT during an intercostal 
invasive procedure (thoracentesis, biliary drainage, liver 
biopsy) in LT recipient (see Fig. 4). We designed also a 
flowchart resuming our management of HT when it occurs 
in LT patients (see Fig. 5). The management of the HT starts 
generally with CT placement. Depending on patient’s hemo-
dynamic and amount of bleeding, CT clamping is not rec-
ommended [21, 22]. Bauman et al. reported that the size of 
CT “does not matter”: in his study, in fact, pigtail catheters 
is as effective as bigger chest tubes in the management of 
HT [23].
When medical support, blood transfusion and chest 
decompression allow stabilization of the patient’s general 
conditions, radiologic embolization could be considered if 
bleeding is persistent. Otherwise, when all these tools are 
inadequate to stabilize patient’s hemodynamic, surgery is 
indicated, with no delay. It is difficult to compare all cases 
and to homogenize to the same attitude all time because 
of different patients, past histories, comorbidities, amount 
of bleeding and availability of therapeutic tools. However, 
we can conclude that an aggressive strategy should not be 
delayed if appropriated, given the vulnerability LT recipi-
ent patients (taking into account for coagulopathy, portal 
hypertension, deficient nutrition status compared to a non-
transplant population).
Given that immunosuppression therapy, moreover, the 
risk of bacterial infection is increased in LT recipients [24]. 
When HT is abundant but stable, thoracoscopy should be 
performed if signs of infection appear, without latency. 
The pleural cavity has to be well cleaned up, as well as for 
non-transplanted patients. The lower impact on respiratory 
parameters of thoracoscopy compared to thoracotomy must 
be considered [25–28].
Fig. 4  Flowchart of the manage-
ment in case of a suspected 
HT (hemothorax) in our LT 
recipients. Hb hemoglobin 
level, VATS video assisted 
thoracoscopy
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Pleural fibrinolytic therapy, suggested by Kumaret al. 
[29] is probably less safe than thoracoscopy in LT recipi-
ents because of uncontrolled bleeding risks. However, series 
are needed to confirm this statement. In any case, we do not 
advise this type of treatment in LT recipients.
This study has several limitations. First of all its ret-
rospective design and t. Second, data are heterogeneous 
because of different attitudes and management strategies in 
different surgical centers.
On the other side, HT is a very rare and fatal complication 
and literature about it and its management in LT recipients 
is really limited.
In conclusion, postoperative hemothorax is due mainly 
to iatrogenic causes in LT recipients. Despite rare, it brings 
high morbidity and mortality rates. All efforts must be done 
to prevent this dramatic complication, paying particular 
attention to coagulation asset and using US guide for all 
invasive maneuvers. Management is challenging, medical 
and interventional tools as CT, RE and surgery are valuables 
tools available. Thoracoscopy should be preferred when sur-
gery is mandatory.
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